Introduction {#Sec1}
============

Dopamine, as a crucial neurotransmitter, can transmit neuronal signals to regulate neurological function by acting on specific dopamine receptors \[[@CR1], [@CR2]\]. Currently, the dopamine receptor family is considered to play a key role in various advanced neural functions, including emotion, reward and autonomic movement \[[@CR3]\]. In addition, increasing attention has been paid to the role of the dopamine signal system in immunomodulation and inflammation control \[[@CR4], [@CR5]\]. Previous studies have shown that the genetic and pharmacologic regulation of dopamine receptors can have potential anti-inflammatory effects. For instance, dopamine D2 receptor (DRD2) activation is widely involved in the alleviation of inflammatory bowel diseases \[[@CR6], [@CR7]\], pancreatic inflammation \[[@CR8]\] and arthritis \[[@CR9]\]. Specifically, DRD1/D2 have been found to be widely expressed not only in neurons and T cells \[[@CR10]\] but also in microglia \[[@CR11]\], indicating that DRD1/D2 might also be potential therapeutic targets for neuroinflammation in the central nervous system (CNS).

Recently, the pharmacologic activation of DRD2 was shown to exert an obvious inhibitory effect on neuroinflammation induced by intracerebral haemorrhage, by regulating the nuclear factor-κB (NF-κB) signalling pathway \[[@CR12]\]. Moreover, new therapies based on DRD2/D3 agonists have been developed for experimental autoimmune encephalomyelitis \[[@CR13]\]. Therefore, treating the microglia-derived inflammatory response by targeting dopamine receptors appears to be a promising therapeutic strategy for neuroinflammation. In particular, dopamine receptors have been found to be highly associated with the inflammasome signalling pathway. Some previous research has suggested that spinal cord injury induces inflammatory cytokine production by activating the nucleotide-binding domain-like receptor protein 3 inflammasome pathway, which is significantly suppressed by DRD1 agonists \[[@CR14]\]. Moreover, DRD2 can also block NLRP3 inflammasome activation in a β-arrestin-dependent manner \[[@CR15]\]. Collectively, these findings provide a potential therapeutic strategy for treating the neuroinflammatory response by targeting the DRD-mediated inflammasome pathway.

*Murraya exotica* L. (Rutaceae) has traditionally been used in China for the treatment of infectious diseases and pains \[[@CR16]\]. Modern pharmacological studies have suggested that *Murraya koenigii* and *M. exotica* possess a wide range of biological activities, including anti-inflammatory, antinociceptive, anti-oxidative stress, anti-mutagenic stress, and chondroprotective and anticancer metastasis effects \[[@CR17], [@CR18]\]. Isosibiricin is a natural bioactive coumarin compound isolated from *M. exotica*. Several studies have indicated that the coumarin derivatives isofraxidin, osthole and urolithin can exert obvious anti-inflammatory activities both in vitro and in vivo \[[@CR19]--[@CR21]\]. Therefore, in this study, we explored the mechanism of the anti-neuroinflammatory effects of isosibiricin in a BV-2 microglial model and highlighted that isosibiricin can significantly inhibit the production of multiple inflammatory mediators induced by bacterial lipopolysaccharide stimulation via targeting the DRD1/D2-dependent inflammasome pathway, providing a potential therapeutic strategy for inflammation-related neurological disorders.

Materials and methods {#Sec2}
=====================

Chemicals {#Sec3}
---------

Isosibiricin (C~16~H~18~ClO~5~; relative molecular mass, 290.32) was isolated from *M. exotica* by our group. SCH 23390 and sultopride were obtained from MedChem Express (Shanghai, China). Nigericin sodium salt was obtained from BioRuler (Beijing, China). Lipopolysaccharide (LPS) from *Escherichia coli* O55:B5 was obtained from Sigma-Aldrich (St. Louis, MO, USA). Polyvinylidene difluoride (PVDF) membranes were obtained from Merck Millipore (Kenilworth, NJ, USA). Antibodies against pro-caspase-1, caspase-1, pro-interleukin (IL)-1β, IL-1β, NLRP3, cyclooxygenase-2 (COX-2), nitric oxide synthase (iNOS), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), rabbit IgG and mouse IgG were obtained from Cell Signalling Technology (Beverly, MA, USA). Antibodies against IL-18 were obtained from Bioway (Beijing, China). Antibodies against DRD1 and DRD2 were obtained from Bioss (Beijing, China).

Mouse strains {#Sec4}
-------------

Balb/c mice (6--7 weeks old) were purchased from the VITAL RIVER Laboratories (Beijing, China). All mice were raised in a specific pathogen-free environment.

Cell culture {#Sec5}
------------

The BV-2 cell line was purchased from the Cell Bank of Peking Union Medical College in China. The cells were cultured in Dulbecco's modified Eagle\'s medium containing 10% fetal bovine serum, 100 U/mL penicillin and 100 mg/mL streptomycin. The cell culture conditions were maintained at 37 °C in a 5% CO~2~ incubator under 95% absolute humidity.

Nitrite oxide analysis {#Sec6}
----------------------

BV-2 cells were treated with isosibiricin (0, 10, 20 and 50 μM) with or without LPS for 24 h. Then, the supernatants were used to analyse the production of nitrite oxide (NO) with a nitric oxide analysis kit (Jiancheng Bioengineering Institute, Nanjing, China)

Enzyme-linked immunosorbent assay {#Sec7}
---------------------------------

BV-2 cells were treated with isosibiricin (0, 10, 20 and 50 μM) with or without LPS. After treatment for 4 h, 100 μL of the cell supernatants was centrifuged at 2000 × *g* for 2 min to evaluate the accumulation of tumour necrosis factor-α (TNF-α). In addition, 100 μL of the cell supernatants was also centrifuged at 2000 × *g* for 2 min to evaluate IL-6 levels 8 h after treatment. The two experiments were carried out with enzyme-linked immunosorbent assay (ELISA) kits (ExCell Bio Company, Shanghai, China) following the manufacturer's protocol.

Bioinformatics analysis {#Sec8}
-----------------------

The cells were collected and RNA was extracted by the RNAprep Pure Cell/Bacteria Kit (Tiangen Biotech, Beijing, China). Target analyses were carried out by the Yuanquan Yike Company (Beijing, China). Amino allyl-labelled antisense RNA was prepared and purified prior to hybridization. Purified, coupled antisense RNA was quantified using NanoDrop ND-1000 to explore the targets affected by isosibiricin.

Transcriptome analysis {#Sec9}
----------------------

Pathway analysis \[[@CR22]\] on isosibiricin was also performed by the Yuanquan Yike Company. After the targets of isosibiricin were determined by amino allyl-labelled antisense RNA hybridization, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment was used to perform the pathway analysis. Signal pathways significantly influenced by isosibiricin compared with LPS were selected.

Western blotting {#Sec10}
----------------

After treatment, the cells were lysed in ice-cold RIPA buffer containing 1% protease inhibitors (Macgene, Beijing, China). Whole-cell proteins were collected by centrifugation at 13000 × *g* for 30 min. The concentration of the total proteins was detected by a protein assay kit (TransGen, Beijing, China). Protein solutions of equal concentration were separated by 10%--15% SDS-polyacrylamide gel electrophoresis and transferred to PVDF membranes. Next, the PVDF membranes were blocked with 5% skim milk at 25 °C for 30 min. Subsequently, the membranes were incubated with primary antibodies at 4 °C for 12 h. After incubation with a second antibody for 1 h, the membranes were developed with SuperSignal West Femto Maximum Sensitivity Substrate. The protein bands were imaged by a Tanon 5200 Imaging Analysis System (Tanon, Shanghai, China). Relative densitometry analysis was carried out by ImageJ software.

Reverse-transcription PCR {#Sec11}
-------------------------

The cells were collected and total RNA was extracted using the RNAprep Pure Cell/Bacteria Kit (Tiangen Biotech, Beijing, China). The mRNA was reverse transcribed using a cDNA synthesis kit (TransGen, Beijing, China). Reverse- transcription PCR (RT-PCR) was performed using a RT-PCR SuperKit (TransGen, Beijing, China) on an Agilent Technologies Stratagene Mx3005P System. A single cycle was carried out at 95 °C for 30 s, 58 °C for 30 s and 63 °C for 30 s, and this cycle was repeated 40 times. The relative transcriptional levels of DRD1 and DRD2 normalized to those of GAPDH was calculated by the comparative 2^−ΔΔCT^ method \[[@CR23]\].

Dopamine receptor agonist analysis {#Sec12}
----------------------------------

HEK293 cells stably expressing DRD1/Gα16 were cultured in 96-well plates for 12 h. After the supernatant was removed, Fluo-4/AM, a calcium fluorescence probe, was added at 37 °C for 40 min in an incubator under 95% absolute humidity. The Fluo-4/AM was removed and a calcium buffer solution was added. FlexStation II was used to measure the levels of Gα16 protein activation induced by isosibiricin (0, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM and 10 μM) at 525 nm. Dopamine was used as a positive control. The EC~50~ was analysed by GraphPad Prism. All experiments were carried out by the National Center for Drug Screening (Shanghai, China).

Immunohistochemistry {#Sec13}
--------------------

Nine Balb/c mice were randomly divided into the control, LPS and isosibiricin groups. The isosibiricin group was treated with isosibiricin (20 mg/kg body weight). After 1 h, both the LPS group and the isosibiricin group were injected intraperitoneally with LPS (2 mg/kg body weight). Then, the brain tissues were sectioned and stained with specific antibodies.

Cycle adenosine monophosphate analysis {#Sec14}
--------------------------------------

BV-2 cells were treated with 50 μM isosibiricin with or without LPS for 24 h. Then, the cell lysates were used to analyse the level of cycle adenosine monophosphate (cAMP) with a cAMP direct immunoassay kit (Bioway, Beijing, China)

Statistical analysis {#Sec15}
--------------------

All experiments were carried out at least three times in triplicate. Statistical analyses were performed by using one-way analysis of variance with GraphPad Prism 6.0 software. Multiple comparisons were performed by comparing the mean of each column with the mean of every other column. Student's *t*-test was used without correcting for multiple comparisons. All data were expressed as the means ± S.D. A *P*-value \< 0.05 was considered to be significant.

Results {#Sec16}
=======

Isosibiricin inhibits the production of inflammatory mediators in LPS-treated BV-2 cells {#Sec17}
----------------------------------------------------------------------------------------

In this study, the anti-inflammatory effect of isosibiricin (Fig. [1a](#Fig1){ref-type="fig"}) was measured by using an NO release assay. As shown in Fig. [1b](#Fig1){ref-type="fig"}, LPS obviously stimulated NO release, which was significantly inhibited by isosibiricin (10, 20 and 50 μM) in a concentration-dependent manner. To evaluate the effect of isosibiricin on other inflammatory factors, the levels of TNF-α and IL-6 were further analysed by ELISA. As shown in Fig. [1c, d](#Fig1){ref-type="fig"}, TNF-α and IL-6 expression was significantly increased upon LPS treatment; however, isosibiricin (10, 20 and 50 μM) inhibited TNF-α and IL-6 production in a concentration-dependent manner. Moreover, COX-2 and iNOS expression was markedly upregulated in LPS-treated BV-2 cells, and isosibiricin reduced COX-2 and iNOS expression in a concentration-dependent manner (Fig. [1e](#Fig1){ref-type="fig"}). Taken together, these findings indicated that isosibiricin can attenuate neuroinflammation by inhibiting the expression of multiple inflammatory mediators in LPS-treated BV-2 cells.Fig. 1Isosibiricin inhibits the productions of inflammatory mediators in LPS-induced BV-2 cells. **a** The chemical structure of isosibiricin. **b**, **c**, **d** Isosibiricin inhibited LPS-induced NO (**b**), TNF-α (**c**) and IL-6 (**d**) productions in BV-2 cells. **e** Isosibiricin inhibited COX-2 and iNOS expressions in BV-2 cells. ^\#\#^*P* \< 0.01 vs. control group. \*\**P* \< 0.01 vs. LPS group

Isosibiricin upregulates DRD1/D2 expression in LPS-treated BV-2 cells and Balb/c mice {#Sec18}
-------------------------------------------------------------------------------------

To investigate the potential mechanism of the anti-inflammatory effect of isosibiricin, transcriptomics coupled with bioinformatics analysis was performed to explore the anti-inflammatory signalling pathway of isosibiricin in LPS-treated BV-2 cells. The results suggested that 1389 genes, including 615 upregulated genes and 774 downregulated genes (59 genes related to inflammation and 32 genes related to the synthesis, storage, release, termination of dopamine and the expression of DRDs) were significantly changed by isosibiricin compared with LPS. Notably, dopamine receptors were most strongly related to isosibiricin treatment (Fig. [2a](#Fig2){ref-type="fig"}). Moreover, KEGG pathway analysis was carried out to explore the pathway affected by isosibiricin. As shown in Fig. [2b](#Fig2){ref-type="fig"}, dopamine activation of the neurological reward system was strongly influenced by isosibiricin. Therefore, we speculated that isosibiricin might exert an anti-inflammatory effect by targeting the dopamine receptor signalling pathway. Nevertheless, isosibiricin did not directly target or regulate the functions of dopamine receptors (Supplementary Table [1](#MOESM2){ref-type="media"}). Thus, we hypothesized that isosibiricin can regulate the expression of dopamine receptors. As shown in Fig. [2c, d](#Fig2){ref-type="fig"}, LPS downregulated the mRNA expression of DRD1 and DRD2, and this was significantly reversed by isosibiricin. In addition, isosibiricin also upregulated DRD1/D2 expression in the CA1 region and cortex of LPS-treated Balb/c mice (Supplementary Fig. [S1a](#MOESM1){ref-type="media"}). Collectively, these observations revealed that isosibiricin can effectively upregulate DRD1 and DRD2 expression in vitro and in vivo, which might represent a crucial anti-inflammatory mechanism.Fig. 2Isosibiricin upregulates dopamine D1/2 receptors expressions in LPS-induced BV-2 cells. **a**, **b** The predicted pathways (**a**) and targets (**b**) of isosibiricin inferred by the differential expressed gene-based method. **c**, **d** Isosibiricin upregulated dopamine D1 receptors (**c**) and dopamine D2 receptor (**d**) expressions in LPS-induced BV-2 cells. ^\#\#^*P* \< 0.01 vs. control group. \*\**P* \< 0.01 vs. LPS group

Isosibiricin inhibits the NLRP3/caspase-1 inflammasome pathway in LPS- or nigericin-treated BV-2 cells and LPS-treated Balb/c mice {#Sec19}
----------------------------------------------------------------------------------------------------------------------------------

It has been reported that the expression of the pro-inflammatory mediator IL-1β significantly increases in DRD2-null mice compared with wild-type mice \[[@CR24]\]. In addition, DRD1 agonists are able to inactivate the NLRP3 inflammasome pathway \[[@CR14]\]. Thus, we detected the effect of isosibiricin on the NLRP3 inflammasome pathway. As shown in Fig. [3a](#Fig3){ref-type="fig"}, isosibiricin significantly reduced NLRP3, caspase-1, IL-1β and IL-18 expression in a concentration-dependent manner, indicating that isosibiricin exerts an inhibitory effect on the NLRP3/caspase-1 inflammasome pathway. Moreover, the NLRP3 inflammasome inducer nigericin was used to activate BV-2 cells and we found that nigericin significantly increased NLRP3, caspase-1, IL-1β and IL-18 expression, which was effectively inhibited by isosibiricin (Fig. [3b](#Fig3){ref-type="fig"}) \[[@CR25]\]. Animal experiments were also carried out to evaluate the anti-inflammatory effect of isosibiricin. As shown in Fig. [3c](#Fig3){ref-type="fig"}, isosibiricin significantly inhibited inflammasome-related IL-1β and IL-18 induced by LPS in the CA1 region and cortex of Balb/c mice. These results suggested that isosibiricin exerts an anti-inflammatory effect via the inhibition of the NLRP3 inflammasome pathway.Fig. 3Isosibiricin inhibits NLRP3/caspase-1 inflammasome pathway in vitro and in vivo. **a** Isosibiricin inhibited inflammasome-related NLRP3, pro-caspase-1, caspase-1, pro-IL-1β, IL-1β, pro-IL-18 and IL-18 expressions in LPS-induced BV-2 cells. Quantification for caspase-1, IL-1β and IL-18 expressions were relative to GAPDH in LPS-induced BV-2 cells. **b** Isosibiricin inhibited inflammasome-related NLRP3, pro-caspase-1, caspase-1, pro-IL-1β, IL-1β, pro-IL-18 and IL-18 expressions in nigericin-induced BV-2 cells. Quantification for caspase-1, IL-1β and IL-18 expressions were relative to GAPDH in nigericin-induced BV-2 cells. **c** Isosibiricin inhibited inflammasome-related IL-1β and IL-18 in the CA1 region and cortex stained with the specific antibodies IL-1β and IL-18. Arrows indicate the activated inflammatory factors. ^\#\#^*P* \< 0.01 vs. control group. \*\**P* \< 0.01 vs. LPS group or nigericin group

DRD1/D2 inhibitors reverse the isosibiricin-mediated inactivation of NLRP3/caspase-1 inflammasome pathway {#Sec20}
---------------------------------------------------------------------------------------------------------

Considering the effect of isosibiricin on dopamine receptors (Fig. [2c, d](#Fig2){ref-type="fig"}) and the inflammasome pathway (Fig. [3a, b](#Fig3){ref-type="fig"}), we hypothesized that isosibiricin might inhibit the inflammasome pathway through dopamine receptors. Therefore, DRD1 and DRD2 inhibitors, SCH 23390 and sultopride were used to investigate whether DRD1/D2 are involved in isosibiricin-mediated anti-inflammatory effects. We found that the anti-inflammatory effect of isosibiricin was significantly reversed upon treatment with SCH 23390 and sultopride. NLRP3, caspase-1, IL-1β and IL-18 expression was markedly increased by SCH 23390 and sultopride (Fig. [4a](#Fig4){ref-type="fig"}). Furthermore, SCH 23390 and sultopride were also used in nigericin-treated BV-2 cells. Similar to what was observed in the LPS-induced experiment, NLRP3, caspase-1, IL-1β and IL-18 expression was reversed in the SCH 23390- and sultopride-treated groups compared with the isosibiricin-treated group (Fig. [4d](#Fig4){ref-type="fig"}). Taken together, the results suggested that DRD1 and DRD2 inhibitors are able to reverse the isosibiricin-mediated inhibition of the NLRP3/caspase-1 inflammasome pathway.Fig. 4Dopamine D1/2 receptor inhibitors reverse isosibiricin-mediated inhibition of NLRP3/caspase-1 inflammasome pathway. **a** SCH 23390 and sultopride reversed isosibiricin-mediated inhibition of NLRP3, pro-caspase-1, caspase-1, pro-IL-1β, IL-1β, pro-IL-18 and IL-18 expressions in LPS-induced BV-2 cells. Quantification for caspase-1, IL-1β and IL-18 expressions was relative to GAPDH in LPS-induced BV-2 cells. **b** SCH 23390 and sultopride reversed isosibiricin-mediated inhibition of NLRP3, pro-caspase-1, caspase-1, pro-IL-1β, IL-1β, pro-IL-18 and IL-18 expressions in nigericin-induced BV-2 cells. Quantification for caspase-1, IL-1β and IL-18 expressions was relative to GAPDH in nigericin-induced BV-2 cells.   ^\#\#^*P* \< 0.01 vs. control group. ^\$\$^*P* \< 0.01 vs. LPS group or nigericin group. \*\**P* \< 0.01 vs. the isosibiricin group

Discussion {#Sec21}
==========

Dopamine agonists (DAs), such as dopamine, act on dopamine receptors to regulate a great diversity of biological functions \[[@CR26]\]. In the past decade, DAs have been mainly used clinically for the treatment of Parkinson's disease and, recently, the development and clinical application of DAs for various other neurological diseases have begun to draw attention from researchers \[[@CR27], [@CR28]\]. Neuroinflammation is an inflammatory response in the CNS characterized by increased microglial over-activation \[[@CR29], [@CR30]\]. Thus, the development of anti-neuroinflammatory agents is of great importance for the treatment of inflammation-related neurological disorders, such as motor paralysis, amyotrophic lateral sclerosis and dementia \[[@CR31]--[@CR33]\].

In the current study, we reported that isosibiricin exerts a significant anti-neuroinflammatory effect on LPS-treated BV-2 cells. LPS is a common inflammation inducer that is used to investigate different types of inflammatory pathology, such as tissue inflammation \[[@CR23]\], vascular inflammation \[[@CR34]\] and myocarditis \[[@CR35]\]. Dopaminergic neurons play an important role in the pathological process of Parkinson's disease \[[@CR36]\], and LPS is widely used to induce neuroinflammation to establish models of Parkinson's disease. In addition, some references have indicated that dopamine receptors are also involved in the regulation of the classical LPS signalling pathway \[[@CR37]--[@CR39]\]. Therefore, LPS was used to induce neuroinflammation and damage dopamine receptors in the substantia nigra \[[@CR40]\].

The potential mechanism of isosibiricin may involve the upregulation of DRD1/D2 expression and the further inactivation of the NLRP3/caspase-1 inflammasome pathway, which results in the blockage of the production of multiple inflammatory mediators. In addition, we used Pipeline Pilot to measure the solubility, intestinal absorption and blood--brain barrier (BBB) level of isosibiricin. Isosibiricin exhibited good solubility in water at 25 °C and was easily absorbed by the intestine. The BBB level was 2, which means that isosibiricin can pass through the BBB. Thus, our study provides an attractive therapeutic methodology for inflammation-associated neurological disorders, as well as an anti-neuroinflammatory lead compound that may become a clinical candidate.

Dopamine receptors were recently discovered as key therapeutic targets involved in immunoregulation and the inflammatory response \[[@CR41]\]. Previously reported active compounds were shown to mainly activate or inhibit dopamine receptors \[[@CR42], [@CR43]\]; however, we found that isosibiricin did not directly activate DRD1/D2 but significantly upregulated the expression of DRD1/D2 mRNA, further promoting DRD1/D2-dependent inflammasome signalling pathway inactivation and blocking inflammatory mediator production. In addition, the level of cAMP was regulated by DRD1/D2, but we detected that isosibiricin did not affect the level of cAMP (Supplementary Fig. [S1b](#MOESM1){ref-type="media"}). These mechanisms are quite different from those of current small molecular regulators, which directly activate DRD1/D2 \[[@CR44]\]. However, the molecular mechanism by which DRD mRNA expression is regulated still needs to be explored. We speculate that some transcription factors, such as NF-κB, Nrf2 and CREB, might be involved in this process.

Dopamine receptors, including five subtypes from DRD1 to DRD5, are seven-transmembrane-spanning G-protein-coupled receptors \[[@CR45], [@CR46]\]. Based on their structures and pharmacological characteristics, dopamine receptors are divided into two major categories: dopamine D1-like receptors (DRD1 and DRD5) and D2-like receptors (DRD2, DRD3, and DRD4) \[[@CR47]\]. Notably, the specific DRD inhibitors SCH 23390 (for DRD1) and sultopride (for DRD2) significantly reversed the inhibitory effect of isosibiricin on the NLRP3 signalling pathway, further supporting the observation that isosibiricin suppresses neuroinflammation by blocking the NLRP3/caspase-1 inflammasome pathway. It is worth mentioning that the regulatory effect of DRD inhibitors on the isosibiricin-dependent inhibition of IL-1β production was more significant in LPS-induced BV-2 cells than in nigericin-induced BV-2 cells. A possible explanation may be that the mechanism by which LPS induces inflammasome signal activation differs from that of nigericin. Meanwhile, isosibiricin-mediated anti-neuroinflammation was highly associated with the canonical LPS-induced neuroinflammation pathway. Of course, further studies are needed to elucidate this speculation.

In conclusion, our observations demonstrated that isosibiricin exerts a marked anti-neuroinflammatory effect via targeting the DRD1/D2-dependent NLRP3/caspase-1 inflammasome pathway. This finding indicates that isosibiricin may a promising candidate molecule for that treatment of neuroinflammation, and that DRD1/D2 may be a key target for inflammatory programmes in neurological diseases.
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